93281-65-3

Basic information

• Product Name: 4-BROMO-N-TERT-BUTYL-BENZENESULFONAMIDE
• Synonyms: N-T-BUTYL 4-BROMOBENZENESULFONAMIDE;4-BROMO-N-TERT-BUTYL-BENZENESULFONAMIDE;4-BROMO-N-TERT-BUTYLBENZENESULPHONAMIDE;4-Bromo-N-tert-butylbenzenesulphonamide 98%;4-Bromo-N-(tert-butyl)benzenesulphonamide98%;4-Bromo-N-Tert-Butylbenzenesulphonamide(WX633089)
• CAS NO: 93281-65-3
• Molecular Formula: C₁₀H₁₄BrNO₂S
• Molecular Weight: 292.19
• Product Categories: blocks;Bromides;Sulfonamides;Aromatic Building Blocks
• Mol File: 93281-65-3.mol
• Article Data: 10

Chemical Properties

• Melting Point: 96-98
• Boiling Point: 355.4 °C at 760 mmHg
• Flash Point: 168.7 °C
• Appearance: /
• Density: 1.419 g/cm³
• Vapor Pressure: 3.13E-05mmHg at 25°C
• Refractive Index: 1.549
• CAS DataBase Reference: 4-BROMO-N-TERT-BUTYL-BENZENESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-N-TERT-BUTYL-BENZENESULFONAMIDE(93281-65-3)
• EPA Substance Registry System: 4-BROMO-N-TERT-BUTYL-BENZENESULFONAMIDE(93281-65-3)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 93281-65-3(Hazardous Substances Data)

Usage

General Description

4-Bromo-N-tert-butyl-benzenesulfonamide is a chemical compound with the molecular formula C10H14BrNO2S. It is a white to off-white solid that is commonly used as a pharmaceutical intermediate in the synthesis of various drugs. 4-BROMO-N-TERT-BUTYL-BENZENESULFONAMIDE has several potential uses, including as an inhibitor of carbonic anhydrase, an enzyme that plays a role in the regulation of carbon dioxide and bicarbonate in the body. It is also used in the production of pesticides, herbicides, and other agrochemicals. Additionally, it has been studied for its potential anti-cancer and anti-inflammatory properties. 4-Bromo-N-tert-butyl-benzenesulfonamide should be handled and used with care due to its potential hazards, including skin and eye irritation, and potential environmental impacts.

InChI:InChI=1/C10H14BrNO2S/c1-10(2,3)12-15(13,14)9-6-4-8(11)5-7-9/h4-7,12H,1-3H3

Upstream product

• 701-34-8 4-bromo-benzenesulfonic acid amide 
• 84379-72-6 1,3-dioxoisoindolin-2-yl 3,3-dimethylbutanoate 
• 75-64-9 tert-butylamine 
• 98-58-8 4-bromobenzenesulfonyl chloride 

Downstream Products

• 1266477-86-4 4-(5-chloro-4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)benzenesulfonamide 

Relevant articles and documents

Organophotoredox-Catalyzed Decarboxylative N-Alkylation of Sulfonamides

We developed an organophotoredox-catalyzed reaction for N-alkylation of sulfonamides with aliphatic carboxylic acid-derived redox active esters as alkylating reagents. Under mild and transition metal-free conditions, a series of functionalized N-alkylated sulfonamides were prepared. This protocol also enabled the functionalization of pharmaceutical drugs bearing a sulfonamide or carboxylic acid moiety. This radical-mediated process allowed the assembly of three components including sulfonamides, redox active esters, and alkenes to yield complex sulfonamides in a one-pot manner.

Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design to Minimize Host Kinase Interactions

Drug resistant tuberculosis (TB) infections are on the rise and antibiotics that inhibit Mycobacterium tuberculosis through a novel mechanism could be an important component of evolving TB therapy. Protein kinase A (PknA) and protein kinase B (PknB) are both essential serine-threonine kinases in M. tuberculosis. Given the extensive knowledge base in kinase inhibition, these enzymes present an interesting opportunity for antimycobacterial drug discovery. This study focused on targeting both PknA and PknB while improving the selectivity window over related mammalian kinases. Compounds achieved potent inhibition (Ki ≈ 5 nM) of both PknA and PknB. A binding pocket unique to mycobacterial kinases was identified. Substitutions that filled this pocket resulted in a 100-fold differential against a broad selection of mammalian kinases. Reducing lipophilicity improved antimycobacterial activity with the most potent compounds achieving minimum inhibitory concentrations ranging from 3 to 5 μM (1-2 μg/mL) against the H37Ra isolate of M. tuberculosis.

PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME

Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human- derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LAD A), insulin tolerance syndromes, obesity, impaired glucose tolerane (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.